**Roles & Responsibilities of Chief Investigator Agreement**

|  |  |
| --- | --- |
| **Study Title:** | Click or tap here to enter text. |
| **Reference No:** | Click or tap here to enter text. |

|  |
| --- |
| **The Chief Investigator (CI) and all members of the research team shall comply with all current regulations as amended from time to time applicable to the performance of the project, including, but not limited to:** |
| NHS Research Governance Framework for Health and Social CareThe Principles of the World Medical Association Declaration of Helsinki Data Protection Act (1998)Relevant professional body guidanceHuman Tissue Act (2004)The Mental Capacity Act (2005)Good Clinical Practice Guidelines (1996) |

|  |
| --- |
| **The CI must not permit the project to commence at any site until a formal letter confirming Sponsor Approval has been received.** Sponsor Approval will be confirmed in writing when the following checks as appropriate to the nature of the study have been verified and evidence received by the Sponsor: |
| Appropriate Health Research Authority Approval (including favourable ethics opinion where needed). Copies of all documentation listed on the Favourable Opinion letter Confirmation that all appropriate Research Management and Governance checks have been completed and approved for each site: ‘Confirmation of Capacity and Capability’. Monitoring arrangements have been discussed, and confirmed through the LU Research Governance Officer as appropriate (where required)Evidence of appropriate permission to access NHS resources for each member of the research team has been received e.g. where a Substantive or Honorary Contract is not held Letters of Access or Honorary Research Contracts/Research Passports have been obtainedThe study is adequately resourced and has been signed off by the R&D finance leadEvidence that all support departments have agreed in writing to provide services requiredAll other relevant permissions have been obtainedConfirmation that the protocol has undergone appropriate scientific and statistical review, and is compliant with the relevant regulations / guidelines |

|  |
| --- |
| **For Multi-site studies ONLY. It is the Chief Investigator responsibility to ensure that:** |
| The Sponsor is consulted **BEFORE** applications to expand the study into additional sites is madeAll documentation relating to the application to additional sites is copied to the SponsorEnsure that no recruitment related activity commences at any site prior to the Sponsor Approval confirmation being received for that siteProvision of monitoring for the project is discussed prior to any applications for the expansion of the study to additional sites are madeAll research staff at additional sites are appropriately trained in accordance with Sponsor requirementsAll members of the Site Study Team are able by knowledge, training and experience to undertake the roles they accept An Investigator Site File containing the essential documents is maintained and inspection ready at each siteAll Sponsor SOPs, are adhered to, in addition to the SOPs of the participating centre if differentAssist with investigations into any alleged research misconduct undertaken by or on behalf of the SponsorMake necessary provision for archiving of essential documents |

|  |
| --- |
| **During the project it is the CI responsibility to ensure that:** |
| The project is conducted in accordance with the approved version of the protocol and subsequent amendments.Delegation of any responsibilities are clearly documented on the Delegation of Authority and Signature Log before study activity commenced, and the Sponsor kept informed of personnel changes. All participants are consented using the correct version of the consent form as well as using the process agreed and documented in the application.Access by Research Ethics and Governance staff to all consent forms is facilitated where necessary to perform audits during the course of the study. Annual reports are submitted to the Research Governance Office before submission to the approving REC. Amendments are submitted to the Sponsor prior to submission to the relevant authorities. Evidence of approval must be provided to the Sponsor prior to their implementation – unless in emergency circumstances. Reporting of Urgent Safety Measures and subsequent management in line with Regulatory requirementsA Trial Master File (TMF) is created, including individual sections for additional sites where required.All relevant Standard Operating Procedures and policies have been made available to research team and a ‘read record’ retained in the study team training file. Annual progress on the anniversary of the Ethics Favourable Opinion are produced and sent to the Sponsor prior to submission to relevant agencies. All communication to the REC and other regulatory bodies are copied to the sponsor representative for authorisation and processing where relevant.Quality control systems for data handling are in place and all data stored on computers which are not part of the local network are adequately encrypted and secure. Quality control systems for the validation of data when using ‘self-built’ software programmes rather than preparatory software are in place. In the case of studies deemed to be of higher risk, an annual meeting between study staff and Sponsor is facilitated. Study is registered as appropriate on a relevant Protocol Registration Scheme.  |

|  |
| --- |
| **At the end of the project, the CI must ensure that:** |
| End of trial notification is completed and sent to the Sponsor for review and processingDocuments relating to the project are archived in accordance with the Archiving policyThe Sponsor is notified of any outputs, publications or changes in service as a result of the project |

|  |
| --- |
| **Chief Investigator Declaration** |
| **I have read the above and agree to adhere to these responsibilities for the project stated above.** |
| **Chief Investigator Name:** | Click or tap here to enter text. |
| **Date:**  | Click or tap here to enter text. |